Objective: To asses thymosin ␤4 specificity as relevant to the diagnosis of Creutzfeldt-Jakob disease (CJD).
C
REUTZFELDT-JAKOB DISease (CJD) is a rare, fatal neurodegenerative disease belonging to the group of transmissible spongiform encephalopathies or prion diseases. A progressive cognitive dysfunction resulting in dementia represents the main clinical sign and most patients show a spectrum of additional neurological disturbances, including symptoms and signs of motor system dysfunction. Considerable progress in understanding prion disease has improved the knowledge on CJD, and several neuropathological and biochemical findings have been reported to support the clinical diagnosis. In particular, in recent years cerebrospinal fluid (CSF) analysis has become increasingly important in the diagnosis of sporadic CJD (sCJD). Currently, the altered levels of some brain-derived proteins in CSF, like the 14-3-3 protein, tau protein, neuronspecific enolase, and S100B protein, accompanied by characteristic clinical manifestations and typical changes on electroencephalogram and magnetic resonance imaging scans, are highly suggestive of the disease. [1] [2] [3] However, the specificity of each diagnostic criterion does not reach 100%. For these reasons, the clinical diagnosis of CJD may sometimes be difficult in routine practice, as well as remaining problematic for differentiating sCJD from other neurological conditions leading to dementia that may resemble the clinical features. Recently, by applying a proteomic gel-free massbased approach using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) protein profiling, increased levels of thymosin ␤4 protein were observed for the first time in the CSF of patients with CJD. 4 The use of an independent immunoassay technique provided validation of these results. To evaluate thymosin ␤4 specificity as relevant to the diagnosis of CJD, and to define the clinical value of this biomarker, we extended the study to a number of other conditions that lead to dementia.
METHODS

SUBJECTS
In detail, patients included were 21 with pathologically proven CJD (7 with the genetic form E200K and 14 with the sporadic form); 15 with frontotemporal dementia (FTD); and 18 with probable Alzheimer disease (AD), all after clinical, neuropsychological, and neuroimaging evaluations according to the Neary et al criteria 5 and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria, 6 respectively. Nine had rapidonset progressive dementia, comprising 6 patients with T2-weighted and fluid-attenuated inversion recovery mediotemporal hyperintensities without atrophy whose diagnosis of limbic encephalitis was made on the features of limbic signs and symptoms (ie, seizures of temporal semiology, disturbance of episodic memory, affective disturbances with prominent mood lability, or disinhibition), 1 with Hashimoto encephalitis, 1 with acute demyelinating encephalitis, and 1 with stiff-person syndrome. A non-cognitively impaired control (NCIC) group consisted of 25 subjects including patients scanned for idiopathic intracranial hypertension and patients with various peripheral nervous system disorders. Furthermore, none of the control group had dementia, past or current acute or subacute central nervous system diseases, or other neurodegenerative disorders. The CSF samples were obtained by lumbar puncture during the care of patients. Once the samples were collected, they were immediately put on ice and visually inspected to assess blood contamination. 7 All CSF samples appeared to be free of blood contamination; thus, the samples were centrifuged at 13 000g for 10 minutes at 4°C to remove insoluble material. Finally, all the samples were divided into aliquots after the addition of a protease inhibitor cocktail (1mM leupeptin, 1mM aprotinin, 0.2mM phenylmethanesulfonylfluoride, and 2mM sodium orthovanadate) and stored at -80°C. Some aliquots of the frozen samples were successively shipped to our laboratory on dry ice and stored at -80°C until further use. Control patients and patients with dementia were selected for the study so that all the CSF samples were comparable in approximate storage time. For each CSF sample, a written informed consent was obtained from the patients under a protocol approved by an institutional review board.
SAMPLE PREPARATION AND MALDI-TOF MS PROFILING
Protein content in the CSF samples was measured by a protein assay (Bio-Rad Laboratories) according to the manufacturer's instruction. Tau protein concentration was estimated by enzymelinked immunosorbent assay (Innotest hTAU-Ag; Innogenetics) according to the manufacturer's instructions. A 14-3-3 protein assay was carried out using Western blotting, as previously reported, 8 and included on each run as internal standards CSF samples both positive and negative for 14-3-3. Moreover, we included CSF samples from patients who did not have CJD but showed a weak positivity for 14-3-3. For the MALDI-TOF protein profiling analysis, an aliquot of each CSF sample, containing approximately 5 µg of total protein, was subjected to a desalting/concentration step over a ZipTip C18 (Millipore Corporation). The eluted samples were typically mixed at a 1:1 volume to volume ratio with 5 mg/mL of ␣-cyano-4-hydroxycinnamic acid in acetonitrile, 50%, and trifluoracetic acid, 0.1%; 1 µL of this solution was deposited onto stainlesssteel target surfaces and allowed to dry at room temperature. Peptide/protein profiles were analyzed using a Voyager DE PRO MALDI-TOF mass spectrometer (PerSeptiveBiosystems) equipped with a 337-nm nitrogen laser and delayedextraction technology. Separate spectra were obtained for a restricted mass-to-charge range of 1000 to 25 000 Da in linearmode geometry by applying an acceleration voltage of 25 kV, and the delayed extraction was maintained at 250 nanoseconds to give an appropriate time lag focusing after each laser shot. Each individual spectrum, representing 5 accumulated subspectra, was obtained using 500 laser shots. The acquired raw spectra were then processed for automated advanced baseline correction and noise filter with Voyager Data Explorer software, version 4.1 (PerSeptiveBiosystems). Finally, the peak area of thymosin ␤4 signal at 4963.7 mass to charge, derived from the total peak list, was normalized as a percentage of the total peak area (individual peak area percentage/total area of peaks). 9 To evaluate intraexperimental variation, each sample was assayed in duplicate; for interexperimental variation, some samples were analyzed on separate days. Thus, the coefficient of variation was calculated. Data from the CJD and NCIC groups were in part the same used in our previous article. 4 
DATA ANALYSIS
The relative peak area (percentage of area) of the thymosin ␤4 MS signal assayed in duplicate, organized in a data set, was analyzed among patients applying the t test. The P values Ͻ.05 were considered significant. The diagnostic accuracy of the thymosin ␤4 biomarker was assessed using a receiver operating characteristic curve analysis. A previously determined optimal cutoff of 1.2% of the area was considered. The sensitivity, specificity, positive predictive value, negative predictive value, and efficiency were calculated. The area under the curve was determined using the Mann-Whitney U value divided by the number of subjects in each group (ie, area under the curve = U/ n1ϫn2, where n1 corresponded to the CJD group and n2, to the NCIC and dementia groups). 10 Table 1 and Figure 1 . A good reproducibility in the measurement of the thymosin ␤4 relative peak area (percentage of area) was observed for each sample both within a single assay and between the assays (coefficient of variation ranging between 5%-10%). The percentage of area of the thymosin ␤4 MS signal significantly increased in the patients with CJD compared with all the other patients. The highest significance was in comparison with the NCIC group (P=10 −10 ); nevertheless, an extremely significant difference was also observed in comparison with the FTD and AD groups (P=10 −7 ). Compared with the rapid-onset progressive dementia group, the thymosin ␤4 level was also elevated even if the significance was reduced (P=.0004). One of the patients with limbic encephalitis demonstrated a high thymosin ␤4 level. Receiver operating characteristic curve analysis using the optimized cutoff value (1.2% area) revealed a sensitivity of 100% and specificity of 98.5% for differentiating CJD from the other patient groups. The area under the curve was calculated to be 0.998 (Figure 2A) . The positive predictive value and negative predictive value were 95% and 100%, respectively. The ARCH NEUROL / VOL 69 (NO. 7), JULY 2012 WWW.ARCHNEUROL.COM 869 efficiency (defined as true positivesϩtrue negatives/total sample size tested) was 99%. We also estimated the specificity excluding the NCIC group from the receiver operating characteristic analysis; in so doing, we observed a negligible difference in the specificity (98%) and an area under the curve of 0.998 ( Figure 2B ). In Table 2 , a full comparison of specificity, sensitivity, positive predictive value, negative predictive value, and efficiency of thymosin ␤4 assay against 14-3-3 and tau proteins is reported. Moreover, we assessed whether any correlation between thymosin ␤4 and tau levels was present among CJD cases, and a good correlation was found (r=0.56; P=.008).
RESULTS
Results are summarized in
COMMENT
There is great interest in developing new specific biomarkers to support antemortem diagnosis of CJD because the 14-3-3 protein, which is the unique protein currently included in the diagnostic criteria, does not always have a high sensitivity. [11] [12] [13] Furthermore, the specificity of this biomarker is poor and many conditions associated with acute neuronal damage may result in a positive CSF 14-3-3 finding, raising questions about the differentiation of sCJD from other neurodegenerative diseases characterized by a rapidly progressive dementia. 14, 15 Comparable sensitivity was revealed for tau protein and S100B especially in the early stage of sCJD, 2 in contrast with the findings of other studies in which tau has been suggested to be the most sensitive marker in the early stage of sCJD. 16, 17 However, the specificity of these proteins in the complex is still poor, and although their association may improve the sensitivity, the specificity often remains suboptimal. The aim of this study was to investigate whether a proper differential diagnosis of CJD could be made using the CSF levels of thymosin ␤4 that were previously reported by our team to be consistently and specifically expressed in the CSF of patients with CJD. 4 Thus, we compared the thymosin ␤4 levels (MS relative peak area) in the CSF of patients with CJD with those of patients with other forms of dementia to assess the differences among groups. The results showed a marked increase of thymosin ␤4 level in all 21 patients with CJD compared with all the other patients, supporting our initial hypothesis. Only 1 patient with limbic encephalitis demonstrated a thymosin ␤4 level higher than the optimized cutoff value (1.2% area). Therefore, this biomarker might reveal a sensitivity of 100% with a specificity of 98.5% for differentiating CJD from the other patient groups. Moreover, a full comparison on the examined samples between the 14-3-3, tau, and thymosin ␤4 biomarkers showed higher value of sensitivity and efficiency for this last protein. The reason for the increased CSF thymosin ␤4 level in CJD, as well as the pathogenic relevance of this protein, is still uncertain. The release of this brain-derived protein into the CSF is likely correlated, like 14-3-3 protein, tau, and neuron-specific enolase, with its leakage following rapid neuronal damage. However, it may have arisen principally from the glial hyperactivation (gliosis) given that thymosin ␤4 has been detected mainly in human glial cells 18, 19 and demonstrated as being upregulated in hyperactivated microglial cells. 20 Although overall function of thymosin ␤4 is known, the effect on the central nervous system has not been completely clarified. There is evidence that thymosin ␤4 is expressed in the developing brain where it regulates outgrowth of growing neuritis on neurons, likely playing a role in neuroprotection, synaptogenesis, axon growth, cell migration, and plastic changes. 21 Insufficient data have been reported on the protein levels of thymosin ␤4 in central nervous system tissue in healthy and pathological conditions. The expression of thymosin ␤4 increases in focal rat brain ischemia 22 and in rat brain after global transient hypoxia, 23 whereas a downregulation of thymosin ␤4 gene expression occurs in prioninfected mouse neuronal cells. 24 Interestingly, an overexpression of thymosin ␤4 has been demonstrated in the glomeruli of rats used as models for segmental glomerulosclerosis, which plays a role in sclerosis interacting with complement proteins. 25 Because there are indications that complement components may be involved in the prion disease, [26] [27] [28] the understanding of the interaction between thymosin ␤4 and complement proteins in the central nervous system might reveal new molecular mechanisms that could be responsible for the neuronal alterations. In summary, based on these findings, despite the fact that the relatively small number of patients might limit the conclusion taken from this analysis, we propose that CSF levels of thymosin ␤4 protein could be effectively used to discriminate CJD from other forms of dementias. 
